SCHEMBL2180144

SCHEMBL2180144

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)Nc4ccc5c(c4)CCC5)c(F)c3)cc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.52
RAB9A P51151 12/20 0.52
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
LMNA P02545 1/20 0.43
THRB P10828 1/20 0.43
KDR P35968 2/20 0.42
CASP3 P42574 2/20 0.41
SENP7 Q9BQF6 2/20 0.41
POLB P06746 3/20 0.41
SDCBP O00560 1/20 0.39
SDC2 P34741 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13719149 1.00 NPC1 (0.52) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL2179560 0.92 NPC1 (0.51) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL13719256 0.91 LMNA (0.44) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL2179818 0.91 LMNA (0.44) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL2178995 0.89 LMNA (0.49) NPC1RAB9ALMNATHRBKDR
SCHEMBL2179002 0.89 LMNA (0.49) NPC1RAB9ALMNATHRBKDR
SCHEMBL2178484 0.87 LMNA (0.51) NPC1RAB9ALMNATHRBSDCBP
SCHEMBL2178978 0.87 LMNA (0.51) NPC1RAB9ALMNATHRBSDCBP
SCHEMBL2180486 0.84 LMNA (0.47) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL2180326 0.84 LMNA (0.47) NPC1RAB9AMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT NPC1 158/4885RAB9A 2039/4885MEN1 3071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.